Mesoblast Limited American Depositary Shares (MESO) Stock Price

MESOStock

$17.44+21.78%52W

Market Cap$2.26B

P/E—

PEG Ratio—

Div yield—

Beta1.06

MESO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.25%

Price vs S&P 500 (4W)19.64%

VGM Score56.53

Book Value / Share (Quarterly)$0.45

P/TBV (Annual)9.46x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)18.97%

Cash Flow / Share (Quarterly)$-0.05

Price vs S&P 500 (YTD)-21.41%

Gross Margin (TTM)57.98%

Net Profit Margin (TTM)-144.33%

EPS (TTM)$-0.07

10-Day Avg Trading Volume3.01M

EPS Excl Extra (TTM)$-0.07

Revenue Growth (5Y)-11.76%

EPS (Annual)$-0.08

ROI (Annual)-14.08%

Gross Margin (Annual)70.17%

Net Profit Margin (5Y Avg)-1079.10%

Cash / Share (Quarterly)$0.10

Revenue Growth QoQ (YoY)1526.81%

ROA (Last FY)-13.02%

Revenue Growth TTM (YoY)1053.16%

EBITD / Share (TTM)$-0.06

ROE (5Y Avg)-17.42%

Operating Margin (TTM)-115.66%

Cash Flow / Share (Annual)$-0.04

P/B Ratio3.90x

P/B Ratio (Quarterly)4.48x

Net Income / Employee (Annual)$-1,261,000

EV / Revenue (TTM)34.36x

Net Interest Coverage (TTM)-4.56x

ROA (TTM)-12.04%

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)1.99x

Quick Ratio (Quarterly)1.35x

3-Month Avg Trading Volume2.99M

52-Week Price Return21.78%

Revenue / Employee (TTM)$807,200

Tangible BV / Share (Quarterly)$0.11

P/S Ratio (Annual)130.30x

Asset Turnover (Annual)0.02x

52-Week High$3.31

Operating Margin (5Y Avg)-873.47%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)-20.16%

Tangible BV CAGR (5Y)9.39%

26-Week Price Return4.68%

Quick Ratio (Annual)1.72x

13-Week Price Return14.95%

Total Debt / Equity (Annual)0.21x

Current Ratio (Quarterly)1.58x

Enterprise Value$2.25B

Revenue / Share Growth (5Y)-25.24%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-13.18%

Revenue / Employee (Annual)$212,300

Pretax Margin (Annual)-592.00%

Cash / Share (Annual)$0.13

3-Month Return Std Dev62.91%

Gross Margin (5Y Avg)-181.16%

Net Income / Employee (TTM)$-1,165,100

ROE (Last FY)-17.10%

Net Interest Coverage (Annual)-5.06x

EPS Basic Excl Extra (Annual)$-0.08

Receivables Turnover (TTM)2.95x

Total Debt / Equity (Quarterly)0.24x

EPS Incl Extra (TTM)$-0.07

Receivables Turnover (Annual)2.25x

ROI (TTM)-13.15%

P/S Ratio (TTM)34.27x

Pretax Margin (5Y Avg)-1082.59%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$0.13

Forward P/E2147.81x

Price vs S&P 500 (52W)3.22%

Year-to-Date Return-9.56%

5-Day Price Return4.68%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-13.09%

Net Profit Margin (Annual)-593.92%

Month-to-Date Return20.00%

Cash Flow / Share (TTM)$-0.16

EBITD / Share (Annual)$-0.07

Operating Margin (Annual)-480.93%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-14.30%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-0.07

P/TBV (Quarterly)18.33x

P/B Ratio (Annual)2.54x

Pretax Margin (TTM)-143.47%

Book Value / Share (Annual)$0.47

Price vs S&P 500 (13W)13.00%

Beta1.06x

P/FCF (Annual)21.10x

Revenue / Share (TTM)$0.05

ROE (TTM)-16.10%

52-Week Low$1.88

vGradeD

gGradeB

mGradeB

vgmGradeC

MESO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	$24.36

About Mesoblast Limited American Depositary Shares

Mesoblast is a commercial-stage biotechnology company developing allogeneic cellular medicines for serious inflammatory and degenerative diseases. Key programs include Ryoncil for steroid-refractory acute graft-versus-host disease and acute respiratory distress syndrome, Revascor for chronic heart failure, and a candidate for chronic low back pain. The company leverages a proprietary adult stem cell technology platform designed for off-the-shelf therapeutic applications.